 |
市場調查報告書
商品編碼
1550704
全球Bortezomib市場：按產品類型、按應用、按最終用戶、按地區Bortezomib Market, By Product Type, By Application, By End User, By Geography |
||||||
預計2024年全球Bortezomib市場規模為2,454萬美元，預計2031年將達3,315萬美元，2024年至2031年複合年成長率為4.4%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 2454萬美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024-2031 |
| 預測 2024-2031 年複合年成長率： | 4.40% | 2031年價值預測 | 3315萬美元 |
Bortezomib（通常稱為 Velcade）是一種蛋白酶體抑制劑，可作為標靶癌症治療藥物。Bortezomib已被證明是治療多發性骨髓瘤和其他癌症的有效選擇。全球癌症盛行率不斷上升，加上老年人口越來越容易罹患骨髓瘤，可能會推動Bortezomib的需求。由於Bortezomib被指定為孤兒藥，製造商正在積極投資該市場。然而，藥物專利到期可能會阻礙市場成長。Bortezomib令人鼓舞的治療功效和不斷擴大的應用可能會在不久的將來為全球Bortezomib市場的成長提供利潤豐厚的機會。
市場動態：
全球Bortezomib市場的成長是由全球癌症負擔日益增加所推動的。市場成長的原因是多發性骨髓瘤盛行率不斷上升、對該疾病的核准增加以及更容易患骨髓瘤的老年人口不斷增加。據美國國家癌症美國稱，2020 年美國報告了超過 15 萬例多發性骨髓瘤病例。此外，與Bortezomib相關的高治療成本和研發成本可能會阻礙市場成長。創新藥的專利將於2015年至2020年間到期，這將鼓勵學名藥的生產，並可能對原廠藥Velcade的銷售產生負面影響。然而，正在進行的評估Bortezomib在其他疾病中的潛力的試驗可能會帶來新的機會。
本研究的主要特點
本報告對全球Bortezomib市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球Bortezomib市場的主要企業進行了分析。
本研究涵蓋的主要企業包括強生公司、工業、Fresenius SE &Co.KGaA、Dr. Reddy's Laboratories Ltd 和 Scion Pharma LLC。
從這份報告中獲得的見解將幫助負責人和公司經營團隊就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球Bortezomib市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球Bortezomib市場的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章 市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管場景
- 產品發布/核准
- PEST分析
- 波特的分析
- 併購場景
第4章全球Bortezomib市場：依產品類型（2019-2031）
- 注射
- 注射用粉劑
第5章全球Bortezomib市場：依應用分類（2019-2031）
- 多發性骨髓瘤
- 套細胞淋巴瘤
- 其他骨髓惡性腫瘤
第6章全球Bortezomib市場：依最終用戶分類（2019-2031）
- 醫院
- 腫瘤門診
- 門診手術中心
- 其他（研究機構、癌症中心）
第7章全球Bortezomib市場：按地區（2019-2031）
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
第8章 競爭格局
- Hikma Pharmaceuticals
- Pfizer
- Meitheal Pharmaceuticals
- Novartis International AG
- Bristol Myers Squibb
- NATCO Pharma
- Teva Pharmaceuticals
- Reddy's Laboratories
- Gland Pharma
- Shilpa Medicare
- Qilu Pharmaceutical
- Scion Pharmaceuticals
- Farmhispania Group
- Coresyn
- Chem-Stone（Guangzhou）
- Hubei Honch Pharmaceutical
- Vinkem Labs
- Icrom
- TAPI Teva
- Chengdu Aslee Biopharmaceuticals
第9章 分析師建議
- Wheel of Fortune
- 分析師觀點
- Coherent Opportunity Map（COM）
第10章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Global bortezomib market is estimated to be valued at USD 24.54 Mn in 2024 and is expected to reach USD 33.15 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 24.54 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.40% | 2031 Value Projection: | US$ 33.15 Mn |
Bortezomib, commonly known as Velcade, is a proteasome inhibitor that acts as a targeted cancer therapy. It has proven to be an effective treatment option for multiple myeloma and other cancers. Increasing prevalence of cancer worldwide along with growing geriatric population susceptible to myeloma can boost demand for Bortezomib. Drug being designated with orphan drug status has encouraged manufacturers to invest in this market. However, patent expiry of the drug can hamper the market growth. Promising therapeutic efficacy and expanding applications of Bortezomib can offer lucrative opportunities for the global bortezomib market growth in the near future.
Market Dynamics:
Global bortezomib market growth is driven by rising cancer burden globally. The market growth can be attributed to increasing incidence rates of multiple myeloma, approval for additional indications, and expanding geriatric population base who are more prone to developing myeloma. As per the National Cancer Institute, more than 150,000 cases of multiple myeloma were reported in the US in 2020. High treatment and R&D costs associated with Bortezomib can hamper the market growth. Patent expiry of innovative drug between 2015 to 2020 has encouraged production of generic versions, and this can negatively impact the sales of branded Velcade. However, ongoing trials evaluating the potential of Bortezomib in other disease indications can present new opportunities.
Key features of the study:
This report provides in-depth analysis of the global bortezomib market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bortezomib market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Takeda Pharmaceutical Company Ltd, Fresenius SE & Co. KGaA, Dr. Reddy's Laboratories Ltd, and Scion Pharma LLC
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global bortezomib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bortezomib market
Detailed Segmentation-
- By Product Type Insights (Revenue, USD Mn, 2019 - 2031)
- Injection
- Powder for Injection
- By Application Insights (Revenue, USD Mn, 2019 - 2031)
- Multiple Myeloma
- Mantle Cell Lymphoma
- Other Hematological Malignancies
- By End User Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals
- Oncology Clinics
- Ambulatory Surgical Centers
- Others (Research Institutes, Cancer Centers)
- By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hikma Pharmaceuticals
- Pfizer
- Meitheal Pharmaceuticals
- Novartis International AG
- Bristol Myers Squibb
- NATCO Pharma
- Teva Pharmaceuticals
- Reddy's Laboratories
- Gland Pharma
- Shilpa Medicare
- Qilu Pharmaceutical
- Scion Pharmaceuticals
- Farmhispania Group
- Coresyn
- Chem-Stone (Guangzhou)
- Hubei Honch Pharmaceutical
- Vinkem Labs
- Icrom
- TAPI Teva
- Chengdu Aslee Biopharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Bortezomib Market, By Product Type
- Global Bortezomib Market, By Application
- Global Bortezomib Market, By End User
- Global Bortezomib Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Bortezomib Market, By Product Type, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Powder for Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
5. Global Bortezomib Market, By Application, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Mantle Cell Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Other Hematological Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
6. Global Bortezomib Market, By End User, 2019-2031, (USD Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Oncology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
- Others (Research Institutes, Cancer Centers)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
7. Global Bortezomib Market, By Region, 2019 - 2031, (USD Mn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 220 - 2031, (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Meitheal Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NATCO Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gland Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shilpa Medicare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Qilu Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Scion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Farmhispania Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Coresyn
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Chem-Stone (Guangzhou)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hubei Honch Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vinkem Labs
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Icrom
- TAPI Teva
- Chengdu Aslee Biopharmaceuticals
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
Capecitabine市場：按配方、分銷管道、最終用戶、藥物類型分類 - 2025-2030 年全球預測
PARP 抑制劑市場：按藥物類型、按應用、按分銷管道、按地區
Capecitabine市場：按適應症、藥物類型和最終用戶分類：2024-2033 年全球機會分析和產業預測
Epirubicin市場：按產品、劑量、應用、分銷管道 - 全球預測 2024-2030
紫杉醇注射液市場，按適應症類型、按應用、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測
全球紫杉醇注射液市場，依癌症類型、配銷通路、地理位置。
全球 PARP 抑制劑市場評估：按藥物類型、應用、最終用戶、分銷管道、地區、機會和預測（2017-2031）
蛋白酶體抑制劑（PI）市場：現況分析與預測（2023-2030）
PARP 抑制劑藥物治療市場：按藥物、適應症、配銷通路- 全球預測 2024-2030
Capecitabine市場至2030年的預測：按類型、適應症、分銷管道、最終用戶和地區進行的全球分析